Torii Pharmaceutical Co Ltd
TSE:4551
Intrinsic Value
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. [ Read More ]
The intrinsic value of one
Torii Pharmaceutical Co Ltd
stock under the Base Case scenario is
3 493.07
JPY.
Compared to the current market price of 3 790 JPY,
Torii Pharmaceutical Co Ltd
is
Overvalued by 8%.
Torii Pharmaceutical Co Ltd's market capitalization is 106.5B JPY.
Torii Pharmaceutical Co Ltd stock price is 3 790 JPY.
Torii Pharmaceutical Co Ltd stock (3 493.07 JPY) is 8% less than its price (3790 JPY).
Torii Pharmaceutical Co Ltd stock price (3790 JPY) is 10% less than its DCF Value (4 196.66 JPY). Open DCF Valuation
Torii Pharmaceutical Co Ltd stock (2 789.47 JPY) is 26% less than its price (3790 JPY). Open Relative Valuation
Torii Pharmaceutical Co Ltd has upside potential of 17% compared to the average analyst price target.
Open Wall St Estimates
Torii Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Torii Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 4% to 5%.
Torii Pharmaceutical Co Ltd's ROE (Return on Equity) has increased in the last 3 years from 3% to 3%.
Torii Pharmaceutical Co Ltd's Revenue has grown by 12% over the past 12 months.
Torii Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Torii Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 7% per year over the next 3 years.
Torii Pharmaceutical Co Ltd has negative Free Cash Flow for the last twelve months.
Torii Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 5%.
Torii Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
Torii Pharmaceutical Co Ltd's Revenue has been growing by 9% per year for the last 3 years.
Torii Pharmaceutical Co Ltd has a very low three-year average ROIC (Return on Invested Capital): 4%. The company is not efficient at using invested capital to generate operating income.
Torii Pharmaceutical Co Ltd has a very low three-year average ROE (Return on Equity): 3%. The company is not efficient at transforming stockholders' equity into net income.
Torii Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Torii Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.
Torii Pharmaceutical Co Ltd's short-term assets (88B JPY) exceed its short-term liabilties (13B JPY).
Torii Pharmaceutical Co Ltd's long-term assets (133B JPY) exceed its long-term liabilties (13B JPY).
Torii Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (44B JPY) than debt (22m JPY).
Torii Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 6.47.
Valuation Backtest
Torii Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Torii Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Torii Pharmaceutical Co Ltd
Balance Sheet Decomposition
Torii Pharmaceutical Co Ltd
| Current Assets | 88.1B |
| Cash & Short-Term Investments | 44B |
| Receivables | 28.5B |
| Other Current Assets | 15.6B |
| Non-Current Assets | 45.3B |
| Long-Term Investments | 34B |
| PP&E | 2.1B |
| Intangibles | 429m |
| Other Non-Current Assets | 8.8B |
| Current Liabilities | 12.5B |
| Accounts Payable | 7B |
| Accrued Liabilities | 931m |
| Other Current Liabilities | 4.6B |
| Non-Current Liabilities | 794m |
| Long-Term Debt | 22m |
| Other Non-Current Liabilities | 772m |
Earnings Waterfall
Torii Pharmaceutical Co Ltd
|
Revenue
|
54.6B
JPY
|
|
Cost of Revenue
|
-29.8B
JPY
|
|
Gross Profit
|
24.8B
JPY
|
|
Operating Expenses
|
-19.8B
JPY
|
|
Operating Income
|
5B
JPY
|
|
Other Expenses
|
-916m
JPY
|
|
Net Income
|
4.1B
JPY
|
Free Cash Flow Analysis
Torii Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Torii Pharmaceutical Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Torii Pharmaceutical Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Torii Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Torii Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Torii Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Torii Pharmaceutical Co Ltd
is 4 437 JPY
with a low forecast of 4 040 JPY and a high forecast of 4 935 JPY.
Shareholder Return
Price
Torii Pharmaceutical Co Ltd
| Average Annual Return | 11.37% |
| Standard Deviation of Annual Returns | 22.55% |
| Max Drawdown | -15% |
| Market Capitalization | 106.5B JPY |
| Shares Outstanding | 28 105 228 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Torii Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
Contact
IPO
Employees
Officers
The intrinsic value of one
Torii Pharmaceutical Co Ltd
stock under the Base Case scenario is
3 493.07
JPY.
Compared to the current market price of 3 790 JPY,
Torii Pharmaceutical Co Ltd
is
Overvalued by 8%.
You don't have any saved screeners yet
